MUSC researchers are tackling MASH, or metabolic dysfunction-associated steatohepatitis, a liver disease affecting hundreds of millions worldwide.
Vous n'êtes pas connecté
Maroc - NEWS.MEDICAL.NET - A la Une - 11/09/2024 06:08
Using a novel stem cell platform, a team of the Medical University of South Carolina researchers has identified a pathway that could be targeted by drugs to reduce fat accumulation in patients with a common form of fatty liver disease known as metabolic dysfunction-associated steatotic liver disease, or MASLD.
MUSC researchers are tackling MASH, or metabolic dysfunction-associated steatohepatitis, a liver disease affecting hundreds of millions worldwide.
A surprising discovery during kidney research has led scientists to a possible new treatment for one of the world’s fastest-growing liver diseases....
A medicine that has been used for decades to treat asthma may one day help people with a serious liver disease that affects millions around the world....
A new study led by researchers from VIB and KU Leuven shows that Parkinson's disease can be divided into distinct subtypes, helping explain why a...
A new study led by researchers from VIB and KU Leuven shows that Parkinson's disease can be divided into distinct subtypes, helping explain why a...
Researchers have developed a stem cell-based model of the...
Fatty liver disease or MASLD is driven by diet, inactivity, diabetes, hepatitis, and medications worldwide.
Fatty liver is often a silent disease. Many young patients remain asymptomatic, with diagnosis occurring incidentally during routine health check-ups....
Impaired mitophagy and the accumulation of damaged mitochondria are key drivers of endothelial cell (EC)dysfunction in diabetic wounds.
Highlights: MASLD affects up to 40% of adults globally 60-70% of people with diabetes may have fatty liver